Clinical Trials
Tonix is committed to improving the lives of patients by identifying, researching and developing promising therapies which have the potential to address unmet needs.
TNX-102 SL
Phase III – Fibromyalgia
A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-102 SL taken daily at bedtime by patients with Fibromyalgia in 30 locations in the US.
For more information, visit https://clinicaltrials.gov/ (NCT05273749) and https://resilientstudy.com/.
To see if you pre-qualify, please visit https://resilientstudy.com/ and click “See if You Qualify” to find a participating site near you. If no sites are found near you, please try again in a month as some sites may be available later.
TNX-1900
Phase II – Chronic Migraine
A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-1900 taken prophylactically on a daily basis to prevent chronic migraine in 25 locations in the US.
For more information, visit: https://clinicaltrials.gov/ (NCT05679908) and https://migrainepreventionstudy.com/
To see if you pre-qualify, please visit https://migrainepreventionstudy.com/ and click “See if You Qualify” to find a participating site near you. If no sites are found near you, please try again in a month as some sites may be available later.
TNX-601 ER
Phase II – Major Depressive Disorder
A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-601 ER taken daily to treat major depressive disorder in 30 locations in the US.
For more information, visit: https://clinicaltrials.gov/ (NCT05686408).
Patient Resources
The below are a few patient advocacy organizations that provide resources and support to those affected by Fibromyalgia: